Vivimed Labs, a supplier of specialty chemicals and pharmaceuticals products, on March 8 has received approval from the Uzbekistan government for two products.

The company received approval for Bilastin tablets and Orzole combi.Bilastin tablets (brand name Flustin) is a second-generation antihistamine used in treating allergic Rhino conjunctivitis and Urticaria (hives).

Orzole combi (Ofloxacin + Ornidazole) is used in treating bacterial and parasitic infections. It is used to treat gastrointestinal infections such as acute diarrhoea or dysentery, gynaecological infections, lung infections and urinary infections.

Both the products are manufactured at the company's Hyderabad-based facility and has been approved by PICS & Health Canada.

Ramesh Krishnamurthy, CEO of Vivimed Labs said, "We are very excited to receive approval to Vivimed's own products. Vivimed strategy is to increase its share of Branded products in CIS Markets. Vivimed shall be launching these products in 2021. Our purpose is to offer innovative & top quality formulations at affordable prices. This approval is testimony to Vivimed's growth strategy."

Shares of the company gained Rs 0.65, or 3.76%, to settle  at  Rs 17.95.  The total volume of shares traded  was  114,551 at  the BSE (Monday).